{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:54:10Z","timestamp":1782896050539,"version":"3.54.5"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University Cancer Research Fund","award":["grant no: 2015-T2-08"],"award-info":[{"award-number":["grant no: 2015-T2-08"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.trsl.2017.06.011","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:31:37Z","timestamp":1498692697000},"page":"59-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Chimeric antigen receptor T-cells for B-cell malignancies"],"prefix":"10.1016","volume":"187","author":[{"given":"Eben I.","family":"Lichtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2017.06.011_bib1","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1182\/blood-2015-12-629089","article-title":"Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies","volume":"127","author":"Sun","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.trsl.2017.06.011_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication stress and cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trsl.2017.06.011_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1098\/rspb.1954.0054","article-title":"Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity","volume":"143","author":"Billingham","year":"1954","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"10.1016\/j.trsl.2017.06.011_bib5","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2017.06.011_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.trsl.2017.06.011_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.trsl.2017.06.011_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0092-8674(05)80059-5","article-title":"Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4","volume":"71","author":"Chen","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2017.06.011_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trsl.2017.06.011_bib10","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1073\/pnas.90.14.6586","article-title":"Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation","volume":"90","author":"Gimmi","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2017.06.011_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2017.06.011_bib12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib14","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib17","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2017.06.011_bib18","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib19","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.trsl.2017.06.011_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.trsl.2017.06.011_bib21","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.06.011_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2014.2525","article-title":"Vector integration and tumorigenesis","volume":"25","author":"von Kalle","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib23","doi-asserted-by":"crossref","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib24","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2017.06.011_bib25","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.06.011_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.trsl.2017.06.011_bib27","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2017.06.011_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.V128.22.1851.1851","article-title":"Direct comparison of in\u00a0vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with B-Cell lymphoma: Reversal of toxicity from tonic signaling","volume":"128","author":"Gomes da Silva","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2015.12.001","article-title":"Chimeric antigen receptor-redirected T cells return to the bench","volume":"28","author":"Geldres","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1016\/j.trsl.2017.06.011_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","article-title":"Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents","volume":"334","author":"Sharifzadeh","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.trsl.2017.06.011_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood.V128.22.329.329","article-title":"Targeting FVIII-specific B cells using BAR-transduced regulatory T cells","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib33","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib34","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib35","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.06.011_bib36","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib38","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.V126.23.2046.2046","article-title":"First clinical application of Talen engineered universal CAR19 T cells in B-ALL","volume":"126","author":"Qasim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.trsl.2017.06.011_bib40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1089\/hum.2011.167","article-title":"Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies","volume":"23","author":"Kebriaei","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/hum.2009.114","article-title":"piggyBac transposon\/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies","volume":"21","author":"Manuri","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib42","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib43","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1089\/hum.2005.16.1241","article-title":"Silencing and variegation of gammaretrovirus and lentivirus vectors","volume":"16","author":"Ellis","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2017.06.011_bib45","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.1512503112","article-title":"Generation of knock-in primary human T cells using Cas9 ribonucleoproteins","volume":"112","author":"Schumann","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2017.06.011_bib46","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib47","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib48","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.06.011_bib49","doi-asserted-by":"crossref","first-page":"17469","DOI":"10.1073\/pnas.0907448106","article-title":"Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity","volume":"106","author":"Hinrichs","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2017.06.011_bib50","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in\u00a0vitro paradoxically impairs the in\u00a0vivo antitumor efficacy of adoptively transferred CD8+ T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.06.011_bib51","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in\u00a0vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib52","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V128.22.219.219","article-title":"CD19CAR T cell products of defined CD4:CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-Cell all","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.102","article-title":"Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells","volume":"34","author":"Turtle","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib55","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.06.011_bib56","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib57","doi-asserted-by":"crossref","first-page":"e1027469","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trsl.2017.06.011_bib58","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood.V126.23.3773.3773","article-title":"Addition of fludarabine to cyclophosphamide lymphodepletion improves in\u00a0vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib59","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib60","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib62","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib63","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib64","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03","year":"2010"},{"key":"10.1016\/j.trsl.2017.06.011_bib65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymthe.2016.11.011","article-title":"The flipside of the power of engineered T cells: observed and potential toxicities of genetically modified T cells as therapy","volume":"25","author":"Bedoya","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib66","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood.V128.22.652.652","article-title":"Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a xenograft model","volume":"128","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib67","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.V128.22.2159.2159","article-title":"Kinase inhibitor ibrutinib prevents cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells (CART) for B cell neoplasms","volume":"128","author":"Ruella","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7002","article-title":"Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r\/r) acute lymphoblastic leukemia (ALL)","volume":"34","author":"Frey","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib69","series-title":"ClinicalTrials.gov [Internet]","article-title":"Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET)","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib70","series-title":"Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results","year":"2017"},{"key":"10.1016\/j.trsl.2017.06.011_bib71","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib72","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.trsl.2017.06.011_bib73","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib74","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.06.011_bib75","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00262-016-1895-5","article-title":"The growing world of CAR T cell trials: a systematic review","volume":"65","author":"Holzinger","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.trsl.2017.06.011_bib76","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.trsl.2017.06.011_bib77","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib78","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2005-08-3503","article-title":"Analysis of transgene-specific immune responses that limit the in\u00a0vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation","volume":"107","author":"Berger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib79","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib80","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib81","series-title":"ClinicalTrials.gov [Internet]","article-title":"3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN)","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib82","series-title":"ClinicalTrials.gov [Internet]","article-title":"A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib83","series-title":"ClinicalTrials.gov [Internet]","article-title":"Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib84","series-title":"ClinicalTrials.gov [Internet]","article-title":"Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas (4SCAR19273)","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib85","series-title":"ClinicalTrials.gov [Internet]","article-title":"A Phase I\/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib86","series-title":"ClinicalTrials.gov [Internet]","article-title":"Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib87","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in\u00a0vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib88","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/S1525-0016(16)38759-7","article-title":"401. Unexpected toxicity of cyclophosphamide followed by adoptively transferred CD19-targeted T cells in a patient with Bulky CLL","volume":"17","author":"Brentjens","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib89","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib90","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib91","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2017.06.011_bib92","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib93","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib94","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib95","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remissions in children with relapsed\/refractory ALL treated with T Cells engineered with a CD19-targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib96","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood.V128.22.221.221","article-title":"Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (all)","volume":"128","author":"Grupp","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib98","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V128.22.2801.2801","article-title":"Efficacy and safety of CTL019 in the first us phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis","volume":"128","author":"Maude","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib99","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V128.22.217.217","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"128","author":"Maude","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib101","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V128.22.587.587","article-title":"Safety and efficacy evaluation of 4SCAR19 chimeric antigen receptor-modified T cells targeting B cell acute lymphoblastic leukemia\u2013three-year follow-up of a multicenter phase I\/II study","volume":"128","author":"Chang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib102","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V128.22.649.649","article-title":"Safety and efficacy of low dose CD19 targeted chimeric antigen receptor T (CAR-T) cell immunotherapy in 47 cases with relapsed refractory B-cell acute lymphoblastic leukemia (B-ALL)","volume":"128","author":"Deng","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib103","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7003","article-title":"Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL","volume":"34","author":"Park","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib104","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V126.23.682.682","article-title":"Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-Cell ALL","volume":"126","author":"Park","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib105","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib106","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib107","article-title":"FDA lifts hold on cancer immunotherapy trial placed after patients died","volume":"354","author":"Dyer","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.trsl.2017.06.011_bib108","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.V128.22.2803.2803","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib109","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood.V128.22.650.650","article-title":"Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL)","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib110","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib111","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8515","article-title":"Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel\/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)","volume":"33","author":"Sauter","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib113","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.trsl.2017.06.011_bib114","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V128.22.56.56","article-title":"CD19 CAR-T cells are highly effective in ibrutinib-refractory chronic lymphocytic leukemia","volume":"128","author":"Turtle","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib115","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib116","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V126.23.184.184","article-title":"Anti-CD19 chimeric antigen receptor-modified T cell Therapy for B Cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in\u00a0vivo expansion and persistence of CAR-T cells and clinical outcomes","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib117","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.V128.22.58.58","article-title":"Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed\/refractory CLL","volume":"128","author":"Geyer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib118","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/blood.V128.22.998.998","article-title":"A phase 2 multicenter trial of KTE-C19 (anti-CD19 CAR T cells) in patients with chemorefractory primary mediastinal B-Cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL): interim results from ZUMA-1","volume":"128","author":"Neelapu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib119","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1182\/blood.V128.22.4192.4192","article-title":"Transcend NHL 001: immunotherapy with the CD19-directed CAR T-cell product JCAR017 results in high complete response rates in relapsed or refractory B-Cell non-Hodgkin lymphoma","volume":"128","author":"Abramson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA3010","article-title":"Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma","volume":"34","author":"Kochenderfer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib121","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V128.22.999.999","article-title":"T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial","volume":"128","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib122","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.V124.21.1982.1982","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL","volume":"124","author":"Porter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib123","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3009","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R\/R) CLL","volume":"34","author":"Porter","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib124","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8516","article-title":"Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"33","author":"Schuster","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib125","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood.V128.22.3026.3026","volume":"128","author":"Schuster","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib126","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1182\/blood.V128.22.1100.1100","article-title":"Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with poor prognosis, relapsed or refractory CD19+ follicular lymphoma: prolonged remissions relative to antecedent therapy","volume":"128","author":"Chong","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib127","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1182\/blood.V124.21.3087.3087","article-title":"Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"124","author":"Schuster","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib129","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood.V126.23.3991.3991","article-title":"Phase 1 clinical results of the ZUMA-1 (KTE-C19-101) study: a phase 1-2 multi-center study evaluating the safety and efficacy of anti-CD19 CAR T cells (KTE-C19) in subjects with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"126","author":"Locke","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib130","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib131","doi-asserted-by":"crossref","first-page":"e0128151","DOI":"10.1371\/journal.pone.0128151","article-title":"Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan Receptor-1 (ROR1) into diverse memory T-cell populations","volume":"10","author":"Deniger","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2017.06.011_bib132","series-title":"ClinicalTrials.gov [Internet]","article-title":"Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib133","series-title":"ClinicalTrials.gov [Internet]","article-title":"Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib134","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.trsl.2017.06.011_bib135","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trsl.2017.06.011_bib136","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.trsl.2017.06.011_bib137","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.06.011_bib138","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor Recognition by T Cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2017.06.011_bib139","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.trsl.2017.06.011_bib140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.trsl.2017.06.011_bib141","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201cOff-the-Shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2017.06.011_bib142","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.06.011_bib143","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/mt.2015.104","article-title":"A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy","volume":"23","author":"Valton","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib144","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2015.197","article-title":"Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases","volume":"24","author":"Osborn","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.06.011_bib145","series-title":"ClinicalTrials.gov [Internet]","article-title":"Study of UCART19 in Pediatric Patients With Relapsed\/Refractory B Acute Lymphoblastic Leukemia (PALL)","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib146","series-title":"ClinicalTrials.gov [Internet]","article-title":"Dose Escalation Study to Evaluate the Safety, Tolerability and Biological Activity of a Single Dose of UCART19 in Patients With Relapsed\/Refractory (R\/R) B-cell Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia (CLL) (CALM)","year":"2000"},{"key":"10.1016\/j.trsl.2017.06.011_bib147","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524417302207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524417302207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T02:12:38Z","timestamp":1692843158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524417302207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":147,"alternative-id":["S1931524417302207"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2017.06.011","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T-cells for B-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2017.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}